Every month I do a roundup of the research that actually moved my thinking — not the headlines that generated the most clicks, but the studies I went back to twice.

Here’s November’s list.


The study I found most interesting

“Meal timing, circadian clocks, and their effects on glycemic control” — Current Opinion in Clinical Nutrition and Metabolic Care, October 2026

This was a review article, not a primary study — but it synthesized about 40 recent papers in a way I found genuinely clarifying.

The main argument: insulin sensitivity follows a strict circadian pattern, and that pattern is set by your body’s central clock (driven by light exposure) and your peripheral clocks (set by when you eat). When these clocks are misaligned — late-night eating, irregular meal timing, shift work — metabolic function suffers in ways that aren’t captured by looking at diet alone.

The practical implication for me: consistent meal timing matters nearly as much as meal composition. Eating at the same time each day, even if the food isn’t perfect, keeps peripheral clocks synchronized and reduces glycemic variability.

The specific thing I changed after reading this: I stopped having my biggest meal late at night. Not dramatically — I moved dinner from 8:30 PM to 7 PM — but it’s a week in and the change in how I sleep is noticeable.


The headline that was overblown

“New study: exercise reverses insulin resistance in just 2 weeks”

This circulated widely in October. The study was real — a small trial showing improved insulin sensitivity after 2 weeks of regular moderate exercise. The headline was technically accurate.

What the headline didn’t mention: the participants were sedentary before the study, and “2 weeks” referred to the first measurable effect appearing, not full reversal. The researchers explicitly noted that the improvements continued growing over 12 weeks.

The underlying science is solid: exercise does improve insulin sensitivity relatively quickly. But “just 2 weeks” framing implies it’s fast and easy, when the more accurate takeaway is “it starts working immediately but keep going.”


The supplement question I keep getting

Readers have been asking about inositol, specifically myo-inositol, for blood sugar and PCOS-related insulin resistance.

The short answer: the evidence for myo-inositol in PCOS specifically is reasonably good — multiple RCTs show improved insulin sensitivity and reduced fasting glucose in women with PCOS. Outside of PCOS, the evidence is thinner.

If you have PCOS and are dealing with insulin resistance: worth discussing with your gynecologist or endocrinologist. If you’re just looking for a general blood sugar supplement: the five I covered in this article have more evidence behind them.


Glen’s November Pick

I’ve been recommending the 7-Day Blood Sugar Reset guide to every new reader. It synthesizes the highest-evidence interventions into a simple daily structure — not a diet, not a meal plan, just a framework.

If you haven’t gotten it yet, it’s free. It’s the starting point I’d use if I were starting from scratch.


What I’m tracking in December

The Lancet Diabetes & Endocrinology is due to publish a large meta-analysis on continuous glucose monitoring (CGM) in people without diabetes. The question: does knowing your glucose levels in real time help people without diabetes make better food choices, and does it reduce A1C over 12 months?

The preliminary results leaked at a conference in September. They’re interesting and somewhat counterintuitive. I’ll cover it when the full paper publishes.


Stay curious,

Glen Carter
Editor, Vital Brief Daily


This content is for educational purposes only and is not medical advice. Research discussed has not been reviewed by the FDA for therapeutic applications.